Sakoda Jon 4
4 · Cascadian Therapeutics, Inc. · Filed Feb 22, 2018
Insider Transaction Report
Form 4
Sakoda Jon
10% Owner
Transactions
- Conversion
Common Stock
2018-02-20$3.30/sh+1,818,000$5,999,400→ 10,882,574 total(indirect: See Note 1) - Conversion
Series E Preferred Stock
2018-02-20−1,818,000→ 0 total(indirect: See Note 1)Exercise: $3.30→ Common Stock (1,818,000 underlying)
Footnotes (2)
- [F1]The Reporting Person is a manager of NEA 15 GP, LLC, ("NEA 15 GP") which is the sole general partner of NEA Partners 15, L.P. ("NEA Partners 15"). NEA Partners 15 is the sole general partner of New Enterprise Associates 15, L. P. ("NEA 15"). NEA 15 is the sole member of Growth Equity Opportunities Fund IV, LLC ("GEO IV"), which is the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares held by GEO IV in which the Reporting Person has no pecuniary interest.
- [F2]Each share of the Series E Preferred Stock is convertible into shares of the Issuer's Common Stock (subject to adjustment as provided in the related certificate of designation of preferences) at any time at the option of the holder, and has no expiration date, provided that the holder will be prohibited from converting Series E Preferred Stock into shares of the Issuer's Common Stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 19.99% of the total number of shares of the Issuer's Common Stock then issued and outstanding, which percentage may be changed at the holders' election to any other number less than or equal to 19.99% upon 61 days' notice to the Issuer.